Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

NCT02223819

Last updated date
Study Location
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida, 33140, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Uveal Melanoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Primary diagnosis of uveal melanoma at least 12 mm in largest basal diameter as clinically determined by the treating investigator. Cytologic determination of diagnosis is not required. Size is based on clinical assessment (e.g. by ultrasound or direct ophthalmoscopy) prior to enucleation or radiation therapy.

- Definitive therapy of the primary uveal melanoma must have been performed within 90 days of initiating protocol therapy.

- High-risk (class 2) uveal melanoma as determined by gene expression profiling

- No evidence of metastatic disease.

- Age ≥18 years.

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 (Karnofsky ≥ 70%.

- Life expectancy of greater than 3 months.

- Able to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels

- Patients must have normal organ and marrow function as defined below:

- Absolute neutrophil count (ANC) >1,000 cells/mm³

- Platelet count >75,000/mm³

- Hemoglobin >9.0g/dL

- Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) <3x upper limited of normal (ULN)

- Total bilirubin <2x ULN

- Alkaline phosphatase <3x ULN

- Serum creatinine <2x ULN or a creatinine clearance > 60mL/min

- Note: Patients with hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin metabolism (e.g., Gilbert syndrome) will be eligible at the discretion of the treating physician and/or the principal investigator.

- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation until 4 months after completion of crizotinib administration. Women of child-bearing potential must have a negative serum pregnancy test within 14 days prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study therapy, and 4 months after completion of crizotinib administration.

- Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- History of another malignancy except for those who have been disease-free for 3 years,
or patients with a history of completely resected non-melanoma skin cancer and/or
patients with indolent secondary malignancies not requiring active therapy, are
eligible. Consult the study Principal Investigator if unsure whether second
malignancies meet the requirements specified above.


- Any major surgery or extensive radiotherapy (except that which is required for
definitive treatment of primary uveal melanoma), chemotherapy with delayed toxicity,
biologic therapy, or immunotherapy within 21 days prior to initiation of study
therapy.


- History of prior crizotinib use.


- Use of other investigational drugs within 28 days (or five half-lives, whichever is
shorter; with a minimum of 14 days from the last dose) preceding the first dose of
study therapy and during the study.


- Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
chemically related to crizotinib.


- Concurrent administration of crizotinib and a strong inhibitor or inducer of CYP3A is
not permitted. Many over-the-counter and dietary supplements also inhibit or induce
CYP3A and thus are prohibited.


- A QT interval corrected for heart rate using the Bazett's formula QTcB ≥ 480 msec.


- Concurrent administration of crizotinib and agents that can cause QTc prolongation is
not permitted.


- Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C
Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection,
which will be allowed). HIV-positive patients on combination antiretroviral therapy
are ineligible because of the potential for pharmacokinetic interactions with
crizotinib. In addition, these patients are at increased risk of lethal infections
when treated with marrow-suppressive therapy.


- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Uveal MelanomaCrizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
NCT02223819
  1. Miami Beach, Florida
  2. New York, New York
  3. New York, New York
  4. Columbus, Ohio
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Official Title  ICMJE Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
Brief Summary The study is designed to determine the 32 month rate of distant relapse in patients with uveal melanoma who are at high risk of recurrence following definitive therapy with surgery or radiation who receive adjuvant crizotinib; and secondarily, the overall survival and disease specific survival in this patient population.
Detailed Description

Uveal melanoma is the most common primary intraocular malignancy in adults, and arises from melanocytes within the choroid plexus of the eye. Melanomas of the ocular and adnexal structures comprise approximately 5% of all melanomas and are biologically and prognostically distinct from cutaneous melanoma. In the United States, an estimated 2000 patients are diagnosed with this disease each year.

The development of metastasis in this disease is common and occurs in approximately 50% of patients with posterior uveal melanoma within 15 years after the initial diagnosis and treatment. Uveal melanoma is thought to be particularly resistant to systemic treatment, and no systemic therapy has yet been demonstrated to improve survival. Drugs commonly used to treat advanced cutaneous melanoma rarely achieve durable responses in patients with uveal melanoma.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Uveal Melanoma
Intervention  ICMJE Drug: Crizotinib

An anti-cancer drug acting as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibitor, used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in a gene called ALK.

Crizotinib will be provided as capsules containing 200 or 250 mg of study medication for oral administration.

Other Name: Xalkori
Study Arms  ICMJE Experimental: Crizotinib
Subjects will receive 48 weeks (12 four-week cycles) of crizotinib 250 mg PO twice a day (BID). Subjects will be evaluated by routine bloodwork and physical exam every 4 weeks while they are receiving crizotinib and during follow up period.
Intervention: Drug: Crizotinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: June 29, 2018)
34
Original Estimated Enrollment  ICMJE
 (submitted: August 20, 2014)
30
Estimated Study Completion Date  ICMJE August 2022
Estimated Primary Completion Date August 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Primary diagnosis of uveal melanoma at least 12 mm in largest basal diameter as clinically determined by the treating investigator. Cytologic determination of diagnosis is not required. Size is based on clinical assessment (e.g. by ultrasound or direct ophthalmoscopy) prior to enucleation or radiation therapy.
  • Definitive therapy of the primary uveal melanoma must have been performed within 90 days of initiating protocol therapy.
  • High-risk (class 2) uveal melanoma as determined by gene expression profiling
  • No evidence of metastatic disease.
  • Age ?18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status ? 1 (Karnofsky ? 70%.
  • Life expectancy of greater than 3 months.
  • Able to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
  • Patients must have normal organ and marrow function as defined below:
  • Absolute neutrophil count (ANC) >1,000 cells/mm³
  • Platelet count >75,000/mm³
  • Hemoglobin >9.0g/dL
  • Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) <3x upper limited of normal (ULN)
  • Total bilirubin <2x ULN
  • Alkaline phosphatase <3x ULN
  • Serum creatinine <2x ULN or a creatinine clearance > 60mL/min
  • Note: Patients with hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin metabolism (e.g., Gilbert syndrome) will be eligible at the discretion of the treating physician and/or the principal investigator.
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation until 4 months after completion of crizotinib administration. Women of child-bearing potential must have a negative serum pregnancy test within 14 days prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study therapy, and 4 months after completion of crizotinib administration.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • History of another malignancy except for those who have been disease-free for 3 years, or patients with a history of completely resected non-melanoma skin cancer and/or patients with indolent secondary malignancies not requiring active therapy, are eligible. Consult the study Principal Investigator if unsure whether second malignancies meet the requirements specified above.
  • Any major surgery or extensive radiotherapy (except that which is required for definitive treatment of primary uveal melanoma), chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to initiation of study therapy.
  • History of prior crizotinib use.
  • Use of other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of study therapy and during the study.
  • Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to crizotinib.
  • Concurrent administration of crizotinib and a strong inhibitor or inducer of CYP3A is not permitted. Many over-the-counter and dietary supplements also inhibit or induce CYP3A and thus are prohibited.
  • A QT interval corrected for heart rate using the Bazett's formula QTcB ? 480 msec.
  • Concurrent administration of crizotinib and agents that can cause QTc prolongation is not permitted.
  • Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed). HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with crizotinib. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02223819
Other Study ID Numbers  ICMJE AAAO8010
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Undecided
Responsible Party Richard D. Carvajal, Columbia University
Study Sponsor  ICMJE Columbia University
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Richard Carvajal, MDAssociate Professor of Medicine at the Columbia University Medical Center
PRS Account Columbia University
Verification Date December 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP